Primary Biliary Cholangitis Treatment MarketSize and Trends

The global primary biliary cholangitis treatment market is anticipated to witness substantial growth during the forecast period (2023-2030). It is projected to expand from US$ 650 million in 2023 to reach US$ 1,174.1 million by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This growth can be attributed to various factors including the increasing prevalence of primary biliary cholangitis. Primary Biliary Cholangitis (PBC) is a chronic autoimmune disease that damages the small bile ducts (cholangiocytes) in the liver.

The global primary biliary cholangitis treatment market is expected to witness significant growth over the forecast period. The rising prevalence of primary biliary cholangitis worldwide is the major factor driving the growth of the market. Other key drivers include the growing aging population, increasing approvals of novel drug therapies, and rising healthcare spending in developing nations. North America currently dominates the market and is expected to continue its dominance in the coming years. This can be attributed to the well-developed healthcare infrastructure and increasing Primary Biliary Cholangitis (PBC) disease incidence in the region. Meanwhile, the Asia Pacific region is likely to emerge as the fastest growing market due to rising healthcare awareness, improving healthcare facilities, and large population base.

Primary Biliary Cholangitis Treatment Market Drivers:

Increasing Prevalence of Primary Biliary Cholangitis: The rising prevalence of primary biliary cholangitis across the globe is one of the major factors fueling the growth of the global primary biliary cholangitis treatment market. With changing lifestyles and increased life expectancy, and liver diseases are on the rise which require effective treatment options. Primary biliary cholangitis treatment have emerged as a revolutionary approach to develop more targeted and efficient drugs to treat such complex diseases. For instance, in June 2021, according to a report published by National Center for Biotechnology Information (NCBI), the pooled point-prevalence rate of primary biliary cholangitis was 22.27 cases per 100,000 inhabitants.
Growing Adoption of Novel Drugs: Primary biliary cholangitis has traditionally been treated with ursodeoxycholic acid (UDCA) as the first-line therapy. However, with close to 40% of patients not responding adequately to UDCA, there was a considerable unmet need for alternative treatment options. This has prompted drug manufacturers to focus on developing novel precision therapies targeting specific disease pathways involved in PBC. In the last 5 years alone, three new drugs have been approved by regulatory agencies like the U.S. FDA and European Medicines Agency (EMA) - obeticholic acid (Ocaliva), fibric acid derivatives such as bezafibrate (Pemptor), and interleukin-12/23 inhibitors like mirikizumab (Kineret). Compared to conventional treatments, these novel drugs have demonstrated higher rates of biochemical response and incomplete biochemical response in clinical trials. For instance, in November 2020, GSK plc., a multinational pharmaceutical and biotechnology company, announced further progression in its R&D pipeline with the presentation of data for linerixibat, an investigational product for the potential treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

Primary Biliary Cholangitis Treatment Market Trends:

Strategic Alliance and Collaboration between Companies: Strategic alliances and collaborations between companies have become increasingly common in the global primary biliary cholangitis treatment market in recent years. By joining forces, companies are able to pool together their complementary strengths like research expertise, clinical trial networks, manufacturing capabilities, and marketing reach to accelerate drug development and better serve patients. For instance, on January 8, 2023, CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd., a pharmaceutical company, for the development and commercialization in Japan of CymaBay’s investigational drug, seladelpar for the treatment of primary biliary cholangitis. Increasing strategic alliances like these indicate companies recognize that collaborating is essential to address the challenges of effectively researching, developing, and commercializing new treatment options for rare diseases like primary biliary cholangitis on a global scale. It ultimately benefits patients by accelerating the availability of novel therapies.